Mar 30, 2026 08:47AM Immix Biopharma completes enrollment for AL amyloidosis trial

Mar 30, 2026 06:42AM Immix Biopharma, Inc. (IMMX) PT Raised to $15 at Mizuho

Mar 27, 2026 11:40AM Immix Biopharma, Inc. (IMMX) PT Raised to $15 at Mizuho

Mar 27, 2026 06:45AM Immix Biopharma, Inc. (IMMX) PT Raised to $15 at H.C. Wainwright

Mar 27, 2026 04:08AM Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens After Q4 Result

Mar 25, 2026 04:44AM Morgan Stanley Starts Immix Biopharma, Inc. (IMMX) at Overweight

Mar 9, 2026 03:29AM Citizens Starts Immix Biopharma, Inc. (IMMX) at Market Outperform

Feb 9, 2026 05:26AM Mizuho Starts Immix Biopharma, Inc. (IMMX) at Outperform

Dec 10, 2025 08:25AM Immix Biopharma, Inc. (IMMX) PT Raised to $12 at H.C. Wainwright

Sep 18, 2025 01:30PM Immix Biopharma surpasses 50% enrollment in AL amyloidosis trial

Sep 12, 2025 06:44AM Immix Biopharma, Inc. (IMMX) PT Raised to $8 at H.C. Wainwright

Aug 6, 2025 12:31PM Immix Biopharma plans partnerships for other serious disease programs

Jul 11, 2025 09:36AM Immix Biopharma reports absence of neurotoxicity in CAR-T trial

Jul 8, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

Jul 7, 2025 09:35AM Immix Biopharma expands trial sites for AL amyloidosis cell therapy

Jun 4, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

Jun 3, 2025 02:56PM Immix Biopharma (IMMX) Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 23, 2025 09:06AM Immix Biopharma (IMMX) announces 14 sites enrolling in NEXICART-2 study

May 22, 2025 04:05PM Immix Biopharma (IMMX) announces positive results for NXC-201

Feb 11, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

Feb 10, 2025 09:35AM Immix Biopharma (IMMX) Receives FDA RMAT Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025 09:34AM Immix Biopharma (IMMX) Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Jan 6, 2025 07:10AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

Dec 19, 2024 09:35AM Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Dec 16, 2024 09:48AM Immix Biopharma (IMMX): Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Dec 10, 2024 09:39AM Immix Biopharma (IMMX) Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Nov 25, 2024 09:32AM Immix Biopharma (IMMX) Presents Positive NXC-201 Data

Oct 3, 2024 07:03AM H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

Sep 19, 2024 09:31AM Immix Biopharma (IMMX) Appoints Raymond Comenzo to its Scientific Advisory Board

Aug 28, 2024 09:32AM Immix Biopharma (IMMX) Expands U.S. Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jun 10, 2024 08:33AM RenovoRx (RNXT) Appoints Ryan Witt as SVP of Head of Corporate Strategy and Partnerships